Given the results of KEYNOTE-062 presented at ASCO 2019, how will you utilize immunotherapy in gastric cancer?

Topics: Gastrointestinal Cancers • Medical Oncology

KEYNOTE-062 showed deep durable responses are possible with upfront pembro, specifically in the CPS >10 subset, with OS advantage when compared to platinum based chemotherapy. Pembro is currently approved as third line in PD-L1+ patients. In light of this data, would you consider upfront IO for patients with high CPS?

Answer from: Medical Oncologist at Academic Institution

Interpretation of Keynote-062 study results is complicated. The primary endpoint was non-inferiority of pembrolizumab alone versus chemotherapy for first line therapy in patients with CPS>1. This primary endpoint was met, however the PFS curves are quite revealing in that chemotherapy arm do...

Comments

Medical Oncologist at Alliance Cancer Specialists
Your answer is very helpful, but I'd especially li...

Answer from: Medical Oncologist at Academic Institution

Keynote-062 was designed to determine the role of pembrolizumab alone or in combination with chemotherapy compared to standard chemotherapy. Patients were randomized to pembrolizumab group vs. chemo+pembro vs. chemo. Pembrolizumab compared to chemotherapy was non-inferior to chemo with a non-...

Related Questions